AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Abstract for the Phase 1b cancer trial results will be presented at the world’s largest haematology conference.
- The latest development is a validation to PTX work in T cell lymphomas, an area of unmet clinical need.
- The ASH conference is due in December 2023 in San Diego.
Prescient Therapeutics Limited (ASX: PTX) is gearing up to present data from a Phase 1b study in T cell lymphomas to some of the world’s prestigious physicians and researchers at the American Society of Haematology (ASH) annual meeting.
In the latest development, the ASX-listed company updated on the acceptance of its abstract for clinical data for poster presentation at the meeting.
About ASH annual meeting
The 65th ASH annual meeting is due on 9 – 12 December 2023 in San Diego, California. It is the most comprehensive and largest haematology conference globally, where researchers, experts, and physicians across the globe gather for discussions on the latest innovations and advancements in the haematological space.
In the 64th year (2022), more than 25,000 attendees were part of the ASH annual meeting.
Data source: Company update
Shares jump over 12%
PTX share price jumped by ~12.5% to trade at AU$0.063 apiece during early morning trade on 17 October 2023.
